CA2265921C - Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose - Google Patents

Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose Download PDF

Info

Publication number: CA2265921C
Authority: CA; Canada
Prior art keywords: lactose; sulfur; tolerance; sublimed sulfur; patients
Prior art date: 1999-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2265921

Other languages

English (en)

Inventor

Airudin S. Khan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-08

Filing date

1999-04-08

Publication date

2000-10-03

1999-04-08 Application filed by Individual filed Critical Individual

1999-04-08 Priority to CA 2265921 priority Critical patent/CA2265921C/fr

1999-09-27 Priority to PCT/CA1999/000893 priority patent/WO2000061155A1/fr

1999-09-27 Priority to AU58448/99A priority patent/AU5844899A/en

2000-10-03 Application granted granted Critical

2000-10-03 Publication of CA2265921C publication Critical patent/CA2265921C/fr

2004-08-24 Priority to US10/942,416 priority patent/US20050079231A1/en

2019-04-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

201000010538 Lactose Intolerance Diseases 0.000 title claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 title abstract description 19
239000008101 lactose Substances 0.000 title abstract description 19
238000000034 method Methods 0.000 title description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 37
229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
239000011593 sulfur Substances 0.000 claims abstract description 8
206010000060 Abdominal distension Diseases 0.000 abstract description 11
235000013336 milk Nutrition 0.000 abstract description 10
239000008267 milk Substances 0.000 abstract description 10
210000004080 milk Anatomy 0.000 abstract description 10
108010005774 beta-Galactosidase Proteins 0.000 abstract description 8
238000002560 therapeutic procedure Methods 0.000 abstract description 8
206010012735 Diarrhoea Diseases 0.000 abstract description 7
208000004998 Abdominal Pain Diseases 0.000 abstract description 6
102100026189 Beta-galactosidase Human genes 0.000 abstract description 6
108010059881 Lactase Proteins 0.000 abstract description 6
229940116108 lactase Drugs 0.000 abstract description 6
208000024891 symptom Diseases 0.000 abstract description 5
108090000790 Enzymes Proteins 0.000 abstract description 3
102000004190 Enzymes Human genes 0.000 abstract description 3
229940088598 enzyme Drugs 0.000 abstract description 3
230000000968 intestinal effect Effects 0.000 abstract description 3
206010023648 Lactase deficiency Diseases 0.000 abstract description 2
235000012054 meals Nutrition 0.000 abstract 1
229930003779 Vitamin B12 Natural products 0.000 description 5
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 5
206010016766 flatulence Diseases 0.000 description 5
235000019163 vitamin B12 Nutrition 0.000 description 5
239000011715 vitamin B12 Substances 0.000 description 5
230000037213 diet Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
208000002881 Colic Diseases 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
206010060926 abdominal symptom Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000015243 ice cream Nutrition 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013379 molasses Nutrition 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
208000002670 vitamin B12 deficiency Diseases 0.000 description 1
235000013618 yogurt Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA 2265921 1999-04-08 1999-04-08 Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose Expired - Lifetime CA2265921C (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
CA 2265921 CA2265921C (fr)	1999-04-08	1999-04-08	Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose
PCT/CA1999/000893 WO2000061155A1 (fr)	1999-04-08	1999-09-27	Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose
AU58448/99A AU5844899A (en)	1999-04-08	1999-09-27	Composition, containing sublimed sulfur, for the treatment of lactose intolerance
US10/942,416 US20050079231A1 (en)	1999-04-08	2004-08-24	Use of ingested sublimed sulfur for the restoration of lactose tolerance in humans with the medical disorder of lactose intolerance

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2265921 CA2265921C (fr)	1999-04-08	1999-04-08	Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose

Publications (1)

Publication Number	Publication Date
CA2265921C true CA2265921C (fr)	2000-10-03

Family

ID=29588565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2265921 Expired - Lifetime CA2265921C (fr)	1999-04-08	1999-04-08	Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose

Country Status (1)

Country	Link
CA (1)	CA2265921C (fr)

1999
- 1999-04-08 CA CA 2265921 patent/CA2265921C/fr not_active Expired - Lifetime

Similar Documents

Publication	Publication Date	Title
Urbancsek et al.	2001	Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus® in patients with radiation-induced diarrhoea
US20120053239A1 (en)	2012-03-01	Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate
Mimori et al.	1996	Thiamine therapy in Alzheimer's disease
CA2338533C (fr)	2009-11-24	Procede servant a traiter une maladie auto-immune
JP2010513359A (ja)	2010-04-30	哺乳動物の大腸内のガス発生及びこれに起因する腹部症状を回避又は低減するための、鉱物質及び場合によっては酢酸生成菌及び／又は酪酸生成菌からなる組成物の使用
EP2110133B1 (fr)	2011-08-24	Agent prophylactique et/ou thérapeutique pour le traitement d'un trouble gastro-intestial fonctionnel
Nicolson	2005	Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function
Gaby	2006	Natural remedies for scleroderma
CN115381924B (zh)	2023-09-05	一种用于神经修复的组合物及其制备方法
CA2265921C (fr)	2000-10-03	Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose
JPWO2018190146A1 (ja)	2020-02-20	アルツハイマー病の治療及び／又は予防のための組成物
EP2106705B1 (fr)	2012-01-04	Utilisation d'une composition, laquelle comprend une lectine végétale, un enzyme protéolytique et un composé de sélénium, destinée à la protection des muqueuses et à la réduction d'autres symptômes de patients atteints de cancer
WO2000061155A1 (fr)	2000-10-19	Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose
Czarnecki et al.	1982	Generalized morphoea successfully treated with salazopyrine
AU2005210181B2 (en)	2010-05-20	Composition, comprising L-serine, L-isoleucine, folic acid and trace elements, for treating psoriasis
JP2025521357A (ja)	2025-07-08	ガラクトオリゴ糖の組成物およびその使用
CN101917983A (zh)	2010-12-15	用于治疗无菌性炎症的组合物
Apple et al.	1978	The syndrome of inappropriate antidiuretic hormone secretion in multiple sclerosis
CN113939340A (zh)	2022-01-14	用于预防、管理或治疗偏头痛相关症状的人乳寡糖及其组合物
Prousky	2011	Treating dementia with vitamin B
EP4463016A1 (fr)	2024-11-20	Supplément nutritif pour améliorer la santé intestinale
Riedl et al.	2018	A Prospective Randomized Placebo-Controlled Multicenter Study on the Efficacy of Intravesical Hyaluronan in Bladder Pain Syndrome/Interstitial Cystitis and Considerations for Designing Future Trials
AU2022222415A1 (en)	2023-08-31	Composition and use thereof
JPH04112823A (ja)	1992-04-14	痴呆治療剤
Talapatra et al.	0	Life threatening hypocalcaemia resulting from hypoparathyroidism and coeliac disease.

Legal Events

Date	Code	Title	Description
1999-11-01	EEER	Examination request
2019-06-10	MKEX	Expiry	Effective date: 20190408